Nosa Med AB (NOSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nosa Med AB (NOSA) has a cash flow conversion efficiency ratio of -0.043x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.78 Million ≈ $-191.34K USD) by net assets (Skr41.06 Million ≈ $4.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NOSA stock market capitalisation for the company's overall valuation and market capitalisation.
Nosa Med AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Nosa Med AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nosa Med AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nosa Med AB ranked by their cash flow conversion efficiency. See NOSA operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eratex Djaja Tbk
JK:ERTX
|
0.189x |
|
Bd Multimedia
PA:ALBDM
|
0.061x |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
-0.026x |
|
Embelton Ltd
AU:EMB
|
0.033x |
|
SILVER DOLLAR RES
F:4YW
|
-0.008x |
|
Impedimed Ltd
AU:IPD
|
-1.053x |
|
Bytes Technology Ltd
LSE:BYIT
|
0.626x |
|
Ugint Co Ltd
KQ:195990
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Nosa Med AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Nosa Med AB from 2016 to 2025. View NOSA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr41.06 Million ≈ $4.42 Million |
Skr-6.39 Million ≈ $-688.20K |
-0.156x | +74.29% |
| 2024-12-31 | Skr16.56 Million ≈ $1.78 Million |
Skr-10.03 Million ≈ $-1.08 Million |
-0.606x | +7.42% |
| 2023-12-31 | Skr26.75 Million ≈ $2.88 Million |
Skr-17.50 Million ≈ $-1.88 Million |
-0.654x | -73.15% |
| 2022-12-31 | Skr18.34 Million ≈ $1.97 Million |
Skr-6.93 Million ≈ $-745.46K |
-0.378x | -137.98% |
| 2021-12-31 | Skr39.10 Million ≈ $4.21 Million |
Skr-6.21 Million ≈ $-668.08K |
-0.159x | +76.94% |
| 2020-12-31 | Skr101.64 Million ≈ $10.94 Million |
Skr-69.96 Million ≈ $-7.53 Million |
-0.688x | -145.24% |
| 2019-12-31 | Skr187.85 Million ≈ $20.22 Million |
Skr-52.72 Million ≈ $-5.67 Million |
-0.281x | -60.30% |
| 2018-12-31 | Skr200.39 Million ≈ $21.56 Million |
Skr-35.09 Million ≈ $-3.78 Million |
-0.175x | -21.13% |
| 2017-12-31 | Skr192.22 Million ≈ $20.69 Million |
Skr-27.78 Million ≈ $-2.99 Million |
-0.145x | -3.44% |
| 2016-12-31 | Skr168.06 Million ≈ $18.09 Million |
Skr-23.48 Million ≈ $-2.53 Million |
-0.140x | -- |
About Nosa Med AB
Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, rest of Europe, the United States, Canada, and internationally. The company offers NOSA allergy filter that filters airborne allergens, such as pollen, pet dander, dust, and mold; NOSA smell training, a smell training medical device to improve the sense of smell for individuals … Read more